Mrinalini Dey DrMiniDey
4 years 10 months ago
It was a pleasure to speak to Dr Bryant England about #multimorbidity in #rheumatoidarthritis with a focus on abstract #1924, to be presented at the #Epidemiology & #PublicHealth abstract session on Tuesday #ACR21: https://t.co/qHws6B3fFf
Watch @RheumNow: https://t.co/OKM7WxIEpR
swethaann23 swethaann23
4 years 10 months ago
The opening quote of the day
#ACR21 @RheumNow https://t.co/gow87jkvfJ
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 10 months ago
#ACR21 Abst#0449:
Ever wish you had a tool to help you predict which PsA pts will progress to radiographic damage?
➡️Proteomic approaches identified 103 candidate biomarker peptides related to 69 proteins that can potentially do so!
@Rheumnow @uptoTate
https://t.co/uUsZlBLTWC
Dr. Antoni Chan synovialjoints
4 years 10 months ago
There are no MRI imaging difference in axSpA with psoriasis, coliitis or iritis. 240 patients in the SASPIC study show psoriatic axSpA similar to axSpA associated with iritis or colitis. Supports the umbrella concept of axSpA @RheumNow #ACR21 Abst#0902 https://t.co/VKTUv22hEJ https://t.co/lOL82ceSn9
Dr. John Cush RheumNow
4 years 10 months ago
RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow & its Faculty.
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 10 months ago
#ACR21 Abst#0285
Calculated 10-yr CV risk ↑ w/in 1st yr of new RA dx in 53 Dutch pts:
➤43% had intermediate (I) or high (H) morbidity risk
➤76% had I or H mortality risk
◘ avg 57yo, 74%♀, 72% HTN, & 57% HLD
*️⃣ Early CV risk assessment critical at RA diagnosis!
@Rheumnow
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 10 months ago
#ACR21 Abst#0452
⭐️Total Body PET/CT (TB-PET/CT) as a tool to identify subclinical PsA at the point of transition from psoriasis (PsO).
➡️Should all pts w/ new dx of PsO have a baseline TB-PET/CT to identify early PsA?
#ACRBest @Rheumnow @uptoTate
https://t.co/IuxVuJgFSd https://t.co/AIuH9CIucy
